Because the amount of SphK1 has been found to be increased in multiple myeloma cell lines and specimens from patients, the combinatorial treatment of 5 μM EGCG and SphK1 inhibitor Safingol was tested. This evidence concerns the gene SPHK1 and plasma cell myeloma.